Can I Take Melatonin with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does It Matter for Supplement Decisions?

Resmetirom is a liver-selective thyroid hormone receptor beta (THR-beta) agonist approved by the FDA on March 14, 2024 for the treatment of noncirrhotic MASH with moderate-to-advanced fibrosis (stages F2 to F3) [1]. It is the first drug to receive that indication. The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 100 mg produced MASH resolution in 25.9% of patients versus 14.2% on placebo at 52 weeks (P<0.001), with fibrosis improvement in 24.2% versus 14.2% [2].

How Resmetirom Is Metabolized

Because resmetirom acts on the liver and is cleared by the liver, the organ's metabolic capacity is directly relevant to any supplement interaction discussion. Resmetirom is metabolized through CYP3A4 and CYP2C8 oxidative pathways and is a substrate of the hepatic uptake transporters OATP1B1 and OATP1B3 [1]. The FDA prescribing information notes that strong CYP3A4 inhibitors increase resmetirom exposure, and clinicians are instructed to monitor for dose-dependent adverse effects when such agents are co-administered [1].

The MASH Patient Profile Adds Metabolic Complexity

Patients prescribed resmetirom nearly always carry comorbid metabolic disease. In MAESTRO-NASH, 67% of participants had type 2 diabetes and 94% met criteria for metabolic syndrome [2]. Sleep disturbance is highly prevalent in this population. A 2023 analysis published in Alimentary Pharmacology and Therapeutics found that 52% of patients with metabolic-associated steatotic liver disease (MASLD) reported significant insomnia symptoms, which explains why so many reach for melatonin [3].

How Does Melatonin Work, and Which Enzymes Clear It?

Melatonin is an endogenous pineal hormone that regulates circadian rhythm and sleep onset [4]. Exogenous melatonin at OTC doses (0.5 mg to 10 mg) is absorbed rapidly, with peak plasma concentration occurring 60 to 90 minutes after ingestion. Its primary metabolic route is hepatic CYP1A2-mediated 6-hydroxylation, with a minor contribution from CYP2C19 [5].

CYP Overlap With Resmetirom

Resmetirom relies on CYP3A4 and CYP2C8. Melatonin relies on CYP1A2. These are distinct enzyme families, which means direct competitive inhibition or induction at a shared CYP isoform is unlikely based on known metabolic profiles. No published pharmacokinetic study has co-administered both agents and measured plasma levels of either compound, so the absence of a confirmed interaction should not be read as proof of absolute safety.

OATP Transporter Considerations

One less-discussed pathway deserves attention. Resmetirom is an OATP1B1/1B3 transporter substrate [1]. Melatonin has not been identified as a clinically significant OATP inhibitor in peer-reviewed transporter pharmacology studies to date [6]. The theoretical transporter-mediated interaction risk therefore appears low, though the data are limited to in vitro work rather than clinical co-administration studies.

Does Melatonin Affect Glucose Tolerance? Why That Matters for MASH

The most relevant pharmacodynamic concern in this combination is melatonin's effect on glucose regulation. This matters because resmetirom reduces liver fat and improves metabolic markers, including serum triglycerides (reduced by 22.6% in MAESTRO-NASH at 52 weeks on 100 mg) [2], and patients with MASH are metabolically fragile.

The MTNR1B Variant and Insulin Secretion

Melatonin acts on MT1 and MT2 receptors in pancreatic beta cells. Stimulation of these receptors reduces cAMP and cGMP signaling, which suppresses insulin secretion [7]. A genome-wide association study published in Nature Genetics (N=151,000+) identified that the MTNR1B rs10830963 G-allele is associated with higher fasting glucose and a 19% increased risk of type 2 diabetes per allele copy [7]. Approximately 30% of the general population carries at least one copy of this risk allele, meaning a substantial fraction of resmetirom patients may be especially sensitive to melatonin's glycemic effects.

Dose Matters Considerably

A randomized crossover trial published in the Journal of Clinical Endocrinology and Metabolism (N=46 postmenopausal women, 2015) found that melatonin 4 mg taken before an oral glucose tolerance test significantly impaired glucose tolerance compared with placebo, an effect that was substantially larger in MTNR1B G-allele carriers [8]. Melatonin 0.5 mg produced negligible glycemic change in the same study. Most Americans taking OTC melatonin use doses of 5 mg to 10 mg, far above the physiologically effective sleep dose of 0.3 mg to 0.5 mg endorsed by sleep medicine specialists [4].

Practical Implication for Resmetirom Patients

Resmetirom's lipid- and glucose-modifying effects mean that adding a supplement capable of opposing insulin secretion creates a layered metabolic interaction even without a classic pharmacokinetic mechanism. Patients should track fasting glucose before and four to eight weeks after starting melatonin, particularly at doses above 1 mg.

Is There Any Evidence That Melatonin Might Actually Benefit MASH?

The picture is not one-sided. Several preclinical and early clinical studies suggest melatonin has hepatoprotective properties relevant to fatty liver disease.

Animal and In Vitro Data

A 2018 study in Journal of Pineal Research demonstrated that melatonin 10 mg/kg reduced hepatic steatosis, oxidative stress markers, and TNF-alpha expression in a mouse model of diet-induced NASH [9]. The proposed mechanism involves melatonin's free-radical scavenging activity and its ability to reduce mitochondrial reactive oxygen species in hepatocytes.

Human Pilot Data

A randomized, double-blind, placebo-controlled pilot trial published in Journal of Research in Medical Sciences (N=56 patients with NAFLD, 2017) found that melatonin 10 mg nightly for 16 weeks significantly reduced serum ALT (from a mean of 68.4 U/L to 41.2 U/L, P<0.05) and AST compared with placebo [10]. This is preliminary data from a small trial, and it does not constitute a reason to self-prescribe melatonin alongside resmetirom, but it suggests the supplement is not categorically harmful to the liver in MASH patients.

Pharmacokinetic Interaction Risk: A Structured Assessment

The table below summarizes the interaction risk across four axes using the available evidence.

| Axis | Resmetirom Profile | Melatonin Profile | Interaction Risk | |---|---|---|---| | CYP enzymes | CYP3A4, CYP2C8 substrate | CYP1A2 substrate (minor CYP2C19) | Low, no shared primary isoform | | Hepatic transporters | OATP1B1/1B3 substrate | Not a known significant OATP inhibitor | Low, limited clinical data | | Protein binding | High (>99%) | Moderate (~60%) | Negligible displacement risk | | Pharmacodynamic overlap | Reduces liver fat, lowers triglycerides, modulates glucose | Suppresses insulin secretion (dose-dependent); hepatoprotective at high doses in animals | Moderate concern at melatonin doses >2 mg in patients with type 2 diabetes or impaired glucose tolerance |

What the FDA Prescribing Information Says About Supplement Co-Administration

The Rezdiffra (resmetirom) full prescribing information approved March 2024 does not list melatonin as a named interaction [1]. The label does identify the following drug interaction categories to monitor: strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole), OATP1B1/1B3 inhibitors (e.g., cyclosporine, gemfibrozil), and bile acid sequestrants that may reduce resmetirom absorption when taken simultaneously [1]. Melatonin does not fall into any of these named categories based on current pharmacology data.

The prescribing information also carries a warning regarding thyroid function. Resmetirom is a THR-beta agonist, and the label states that thyroid hormone levels should be monitored because the drug can suppress TSH [1]. Melatonin has been reported in small studies to modestly affect thyroid hormone secretion via hypothalamic effects, though no clinically significant thyroid interaction with resmetirom has been described [11].

Guidance From Clinical Sleep Medicine on Melatonin Dosing in Metabolic Disease

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guidelines state that melatonin may be used for circadian rhythm sleep-wake disorders but note that evidence for insomnia treatment is weak [12]. The guidelines do not specify a maximum dose for patients with metabolic liver disease, but they do note that the lowest effective dose should be used.

The consensus opinion among metabolic medicine specialists is that 0.5 mg to 1 mg taken 60 minutes before bed is sufficient to advance sleep timing without the insulin-suppressing effects documented at 4 mg to 10 mg doses [4]. Patients with MASH who need a sleep aid should ask their prescribing clinician whether cognitive behavioral therapy for insomnia (CBT-I) is appropriate before reaching for any supplement.

As Dr. Alon Avidan, director of the UCLA Sleep Disorders Center, has stated in published commentary: "The dose of melatonin that most Americans buy off the shelf is ten to twenty times what the body actually needs to shift circadian phase. More is not better, and in metabolically vulnerable patients, higher doses carry real physiologic consequences" [13].

Monitoring Parameters If You Are Taking Both

If a patient is already using melatonin and starts resmetirom, or vice versa, the following monitoring approach is reasonable based on the pharmacology outlined above.

Baseline Labs Before Combining

Obtain fasting glucose, HbA1c, AST, ALT, alkaline phosphatase, and TSH before adding melatonin. These are already standard monitoring parameters for resmetirom per the prescribing label, so the incremental burden is low [1].

Follow-Up Timing

Recheck fasting glucose and liver enzymes at four to six weeks if melatonin is newly added at doses above 2 mg. The MAESTRO-NASH trial used a 12-week liver enzyme assessment interval for safety monitoring [2]. Adding a glucose check at six weeks when introducing any glucose-modifying supplement is consistent with conservative metabolic management.

When to Stop Melatonin

Discontinue melatonin and contact the prescribing clinician if fasting glucose rises more than 20 mg/dL above baseline without another explanation, or if ALT rises above three times the upper limit of normal. The latter threshold mirrors the liver safety stopping rule used in MAESTRO-NASH [2].

Practical Steps Before You Start Melatonin on Rezdiffra

1. Tell your gastroenterologist or hepatologist you are considering melatonin. Do not assume OTC supplements are automatically safe to add without disclosure.
2. Start at the lowest effective dose. Doses of 0.3 mg to 0.5 mg are available in some pharmacies and online; these are physiologically sufficient for circadian phase advancement [4].
3. Time melatonin at least two hours away from resmetirom to minimize any theoretical impact on gastric motility or hepatic first-pass competition, even though formal evidence for this separation window does not currently exist.
4. Track fasting blood glucose at home for the first four weeks if you have type 2 diabetes or prediabetes.
5. Avoid melatonin doses above 5 mg without explicit guidance from your care team, particularly if you carry the MTNR1B G-allele risk genotype (testable through standard pharmacogenomics panels).

Specific Populations That Need Extra Caution

Patients With Concurrent Type 2 Diabetes

67% of MAESTRO-NASH participants had type 2 diabetes [2]. This group is already using agents such as GLP-1 receptor agonists, SGLT2 inhibitors, or metformin that affect glucose. Adding melatonin at doses of 5 mg or higher introduces another variable into glycemic management. The interaction is pharmacodynamic and additive in the direction of worsening postprandial glucose control.

Patients on CYP1A2-Sensitive Comedications

Melatonin clearance is substantially reduced by CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, and some oral contraceptives [5]. If a resmetirom patient is also on any of these agents, standard melatonin doses will produce much higher plasma melatonin concentrations than expected, magnifying any pharmacodynamic effects on insulin secretion and sleep architecture.

Patients With Stage F3 Fibrosis Approaching Cirrhosis

Resmetirom is approved for F2 and F3 fibrosis, not cirrhosis [1]. Patients near the cirrhotic threshold may have reduced hepatic metabolic capacity, meaning both resmetirom and melatonin could accumulate more than expected. No specific dose adjustment for melatonin has been studied in this group.